Business Context and Reporting Period
This Form 8-K was filed by Corvus Pharmaceuticals, Inc. on December 13, 2017. The company is an emerging growth company incorporated in Delaware. The report details executive compensation adjustments approved by the Board of Directors on the date of the report.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation changes.
Material Changes
On December 13, 2017, the Board approved the following changes effective for 2018:
- Salary Increase: The Chief Financial Officer's annual salary was increased to $320,000.
- Stock Option Awards: New stock options were granted to the Chief Executive Officer and Chief Financial Officer under the 2016 Equity Incentive Award Plan.
- Grant Terms: Options vest in equal monthly installments over 48 months, subject to continued service. The exercise price equals the closing price of the Company's common stock on the NASDAQ Global Market on the grant date.
| Executive Officer | 2018 Annual Salary | Stock Option Award (Shares) |
|---|---|---|
| Richard A. Miller, M.D. (CEO) | $300,000 | 125,000 |
| Leiv Lea (CFO) | $320,000 | 40,000 |
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies beyond the standard vesting conditions for the equity awards.
Investor Verification Checklist
- Verify the closing stock price on December 13, 2017, to determine the exercise price of the granted options.
- Review the 2016 Equity Incentive Award Plan for specific terms regarding vesting acceleration or forfeiture.
- Confirm the total number of shares available for issuance under the equity plan to assess dilution impact.